Main > > >ONCOLOGY>CHEMOTHERAPY. *

Closed System Drug-Transfer Device.
USA Clearance Date: 2015. 07.24.
(*) Companies; Patents; TradeMark &
Web-Site Available on Request.
UpDate: 2021. 04.02.




Hair Loss Prevention: Scalp Cooling Sys-
tem.
AU 4G Approval Date : 2019. 09.19.
EU 4G CE Mark Date : 2019. 03.27.
USA 4G Approval Date: 2019. 06.27.
(*) Company; Patents; Product Name &
Web-Site Available on Request.
UpDate: 2021. 03.06.




Nausea and Vomiting. TREAT.:
Dronabinol Capsules. Brand.
USA Approval Year: 1985.
(*) Company : AbbVie.
Patent : Expired
TradeMark: Marinol
Web-Site : marinol.com/
UpDate: 2018. 12.23.




Nausea and Vomiting. TREAT.:
Dronabinol Capsules. Generic.
USA Approval Date: 2018. 05.21.
(*) Company: Lannett Company Inc.
www.lannett.com
UpDate: 2018. 05.22.




Nausea and Vomiting. TREAT.:
Fosaprepitant for Injection. Generic.
USA Launch Date: 2019. 09.11.
(*) Company: Dr. Reddy s Laboratories
Ltd.
UpDate: 2020. 01.12.




Neutropenia. TREAT.: Filgrastim Inj.
BioSimilar.
USA Approval Date: 2018. 07.20.
(*) Company : Pfizer.
TradeMark: NIVESTYM
UpDate: 2018. 07.21.




Neutropenia. TREAT.: PegFilgrastim Inj.
BioSimilar.
EU Approval Date : 2018. 09.21.
USA Approval Date: 2018. 11.02.
(*) Company : Coherus BioSciences
TradeMark: UDENYCA
UpDate: 2018. 11.06.




Neutropenia. TREAT.: PegFilgrastim Inj.
BioSimilar.
USA Approval Date: 2018. 06.05.
(*) Company : Mylan
TradeMark: Fulphila
UpDate: 2018. 06.06.




Neutropenia. TREAT.: PegFilgrastim Inj.
BioSimilar.
EU Marketed Since: 2018.
USA Approval Date: 2019. 11.05.
(*) Company : Sandoz.
TradeMark: Ziextenzo
UpDate: 2020. 01.12.




Onco.>Anemia. Treat.: Darb- Epoietin-Alfa Inj.
Non-Myeloid Cancers.
ReCombinant Long Lasting Erythropoitin.
Sialylated Erythropoietin.
USA Approval Date: ?
(*) Company : Amgen.
Patent : Expired
TradeMark: Aranesp
Web-Site : www.aranesp.com/
UpDate: 2018. 09.21.




Onco.>Anemia. Treat.: Epoetin Alfa. (U)
Approval Date: ?
ReCombinant Erythropoietin
(*) Companies; Patents; TradeMarks &
Web-Sites Available on Request.
UpDate: 2018. 09.23.

Onco.>Anemia. Treat.: Epoetin Beta. (C)
ReCombinant Erythropoietin.
Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.




Onco.>AnthraCycline ExtraVasation. AntiDote: Dexrazoxane.HCl for Inj.
USA Approval Date: 2017. 07.10.
USA Launch Date : 2017. 09.25.
(*) Companies; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.21.




Onco.>Hair Loss Prevention: Scalp Cooling.
(*) Company; Patent & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.21.




Onco.>HyperUricemia>Treat.: Febuxostat. (J)
EU Approval Date: 2015. 04.
JP Approval Date: 2016. 05.23.
(*) Company; PR Web-Site & TradeMarks
Available on Request.
UpDate: 2018. 09.18.



Onco.>Induced Nausea & Vomiting
Treat.: Aprepitant Capsules; for Oral
Suspension. (U)
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Induced Nausea & Vomoting
Treat.: Aprepitant Inj. Emulsion. (U)
USA Approval Date: 2017. 11.09.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Induced Nausea & Vomiting
Treat.: Cannabinoid Dronabinol Oral Solution CII.
Version of TetraHydroCannabinol.
USA Approval Date: 2016. 07.05.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Induced Nausea & Vomiting
Treat.: Extended Release Granisetron Inj. (U)
USA Approval Date: 2016. 08.10.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Induced Nausea & Vomiting Treat.: Granisetron Inj.
(*) Company : Roche
Patent : Expired 2007. 12.29.
TradeMark: Kytril
UpDate: 2018. 09.18.




Onco.>Induced Nausea & Vomiting.
Treat.: Granisetron TransDermal System.
(J)
USA Approval Date: 2008. 09.12.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.



Onco.>Induced Nausea & Vomiting.
Treat.: Netupitant+Palonosetron Cap. (C)
EU Approval Date: 2015. 05.27.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.




Onco.>Induced Nausea & Vomiting. Treat.: Palonosetron.HCl Inj. (C)
EU Approval Date : 2015. 05.27.
USA Approval Date: 2003. 07.25.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.18.




Onco.>Induced Nausea & Vomiting. Treat.: Palonosetron.HCl Inj. (I)
Generics.
USA Launch Date: 2018. 03.23.
(*) Company Available on Request.
UpDate: 2018. 09.18.




Onco.>Induced Nausea & Vomiting. Treat.: Palonosetron.HCl Inj. (K)
(*) Company; Patent & Web-Site Availa-
lable on Request.
UpDate: 2018. 09.21.




Onco.>Induced Nausea & Vomiting. Treat.: Rolapitant.
- IV Form:
USA Approval Date: 2017. 10.25
USA Launch Date : 2017. 11.28
- Tablet Form:
EU Approval Date : 2017. 04.26
USA Approval Date: 2015. 09.01
NeuroKinin-1 Receptor AntAgonist
(*) Company; Patents; TradeMarks & Web-
Site Available on Request.
UpDate: 2018. 09.23.


Onco.>Neutropenia. Treat.: Filgrastim. BioSimilar. (C)
USA Launch Date: 2015. 07.22.
(*) Company; TradeMark & Web-Site Avai-
lable on Request.
UpDate: 2018. 09.18.




Onco.>Neutropenia. Treat.: Filgrastim. BioSimilar. (S)
(*) Company : SciGen Ltd.
TradeMark: SciLocyte
UpDate: 2018. 09.21.




Onco.>Neutropenia. Treat.: Filgrastim. Brand. (U)
Approved.
Mechanism: GCSF.
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Neutropenia. Treat.: PegFilgras-
tim. Brand.
Long Acting Version of Filgrastim
USA Approval Date: 2002. 01.31.
(*) Company : Amgen
Patents : Expired
TradeMark: Neulasta
Web-Site : www.neulasta.com
UpDate: 2018. 09.23.




Onco.>Neutropenia. Treat.: Sargramostim.
USA Approval Date: ?
(*) Company; Patents; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




Onco.>Peptide. Thymosin Alpha 1,
TA1; Thymalfasin
USA Approval Date: ?
Utility>Decrease in Side Effects
>Increase in Effectiveness
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 09.23.




OverDose of 5-FluoroUracil &/or Capeci-
tabine. Treat.: Uridine Triacetate Oral
Granules.
USA Approval Date: 2015. 12.11.
(*) Company : BTG Intl.
Patent : Expired
TradeMark: Vistogard
Web-Site : www.vistogard.com
UpDate: 2018. 10.21.




OverDose of Methotrexate. Treat.: Glu-
carpidase 1000 units vial for IV Inj.
USA Approval Date: 2012. 01.18.
USA Launch Date: 2012. 04.30.
(*) Company : BTG Intl.
TradeMark: Voraxaze.
Web-Site : www.voraxaze.com
UpDate: 2018. 10.21.




OverDose of Methotrexate. Treat.: Levo-
Leucovorin+Na for Inj.
USA Approval Date: 2018. 10.23.
(*) Company; Patent; TradeMark & Web-
Site Available on Request.
UpDate: 2018. 10.28.




Sensitivity Assay.
(*) Company : Pieran Holdings Inc.
TradeMark: ChemoINTEL
Web-Site :
pierianbio.com/project/chemo-intel/
UpDate: 2018. 09.23.





>ONCOLOGY>CHEMOTHERAPY. *'s products
This section has no products